Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

Switching from finasteride to dutasteride for treating hair loss, with reports of improved regrowth and little to no side effects.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

Topical finasteride combined with minoxidil is used for hair loss treatment, with some users experiencing fewer side effects compared to oral finasteride. Morr-F, a topical solution, shows better results than minoxidil alone, with minimal adverse effects reported.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user has been using finasteride, minoxidil, microneedling, PRP, and ProCell therapy for hair loss but sees no progress after nine months. They are considering switching to dutasteride and possibly a hair transplant, with suggestions to add oral minoxidil.

Topical dutasteride is more effective than oral finasteride for male pattern hair loss, with fewer side effects. Some prefer oral treatments for convenience, while others use topical solutions like minoxidil and dutasteride, sometimes with microneedling, for better results.

A 22-year-old shared his 15-month progress using finasteride and 12-month progress with minoxidil for hair loss, noting improved thickness but minimal hairline change. He experienced initial shedding with minoxidil but no side effects from finasteride, and he advises patience and consistency for results.

A 31-year-old woman is using Dutasteride (0.5mg daily) and supplements like a multivitamin, Herbadal, pumpkin seed oil, and vitamin D for genetic hair loss, noticing thicker hair but no new growth after one month. She is considering adding minoxidil and is aware of Dutasteride's risks, especially regarding pregnancy.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

A 23-year-old male experiencing worsening hair loss has tried topical Minoxidil, Finasteride, Progesterone, Hydrocortisone butyrate, and Ketoconazole. He is considering switching to oral Finasteride due to concerns about side effects and lack of improvement.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

Minoxidil alone is often insufficient for treating hair loss because it doesn't address the DHT-related cause. Combining it with finasteride, a DHT blocker, is generally more effective.

Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

The user has been on dutasteride for 4.5 months after switching from finasteride due to hair thinning, and is experiencing significant hair loss despite also using minoxidil and microneedling. Many responses suggest that dutasteride takes time to show results, often requiring patience for up to a year or more, and recommend not stopping finasteride abruptly to avoid shedding.

A 22-year-old switched from finasteride to dutasteride for hair loss treatment, also using RU58841, and is managing hypothyroidism. Despite ongoing shedding, they report some improvement and plan to continue dutasteride for a year before considering minoxidil.

Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.

The user had high DHT levels after 8 months on dutasteride, questioning the drug's authenticity. They got dutasteride from a legitimate source and will update on progress.

A 43-year-old experienced gynecomastia after 20 years of taking dutasteride and 7.5mg oral minoxidil. Suggestions include consulting an endocrinologist, checking hormones, and considering Nolvadex or DIM supplements.

Microneedling combined with minoxidil and finasteride shows significant hair regrowth, though opinions on its effectiveness vary. Some users report substantial benefits, while others highlight the need for more research and consistency in application.

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.